UCB transfers back to Recordati the rights for the sale of Corifeo(R) (Lercanidipine) in Germany
UCB announced that it has reached an agreement with Recordati to transfer back the sales and marketing rights in Germany of Corifeo®, an antihypertensive calcium channel blocker, for a payment to UCB of 10 million euros.
"This transaction is another step taken by UCB in its strategy to focus on innovation for specialists particularly in the fields of the central nervous system, inflammation (including allergy) and oncology," declared Bill Robinson, Executive Vice President Global Operations of UCB.
Most read news
Organizations
Other news from the department research and development

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.